Back
ESC Premium Access

Effect of empagliflozin in hfref patients treated with angiotensin receptor neprilysin inhibitor an analysis of EMPIRE HF

Session: Congress committee e-posters choice in heart failure
Topic: Heart Failure with Reduced Ejection Fraction (HFrEF)
Speaker: Doctor M. Omar (Odense, DK)
Event: ESC Congress 2021 - The Digital Experience

Presentation

0

About the speaker

Doctor Massar Omar

Odense University Hospital, Odense (Denmark)
0 follower

46 more presentations in this session

Impact of changes in weight and haematocrit on the reduction in systolic office and ambulatory blood pressure with empagliflozin in patients with type 2 diabetes

Speaker: Doctor A. Sharma (Montreal, CA)

Access
Abstract
Slides
0
Thumbnail

SGLT-2 inhibitors in patients with and without a history of heart failure: a meta-analysis

Speaker: Doctor V. Razuk (New York, US)

Access
Abstract
Slides
0
Thumbnail

Cardiovascular outcome in patients treated with SGLT2 inhibitors for heart failure: a meta-analysis

Speaker: Doctor G. Gager (Vienna, AT)

Access
Abstract
Slides
0
Thumbnail

Reduced tissue sodium content is related to improvement of vascular function in patients with chronic heart failure treated with the SGLT2 inhibitor empagliflozin

Speaker: Doctor J. Kolwelter (Erlangen, DE)

Access
Abstract
Slides
0
Thumbnail

Efficacy and safety of vericiguat in patients with HFrEF treated with sacubitril/valsartan: results from the VICTORIA trial

Speaker: Doctor M. Senni (Bergamo, IT)

Access
Abstract
Slides
0
Thumbnail

Access the full session

Congress committee e-posters choice in heart failure

Speakers: Doctor M. Omar, Doctor A. Sharma, Doctor V. Razuk, Doctor G. Gager, Doctor J. Kolwelter...
Access
0
Thumbnail

About the event

Image

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Congress
logo Image

Related content

ESC Premium Access

Endotrophin is significantly associated with disease severity and increased risk of adverse outcome in HFpEF but not in HFrEF patients

27 August 2021

ESC Premium Access

Urate lowering therapy is associated with a lower risk of heart failure hospitalisation or mortality in hyperuricaemic patients with heart failure: a comparative effectiveness study

27 August 2021

ESC Premium Access

Cardiovascular protection by combination of the selective nonsteroidal MR antagonist finerenone and the SGLT2 inhibitor empagliflozin in a preclinical model of hypertension-induced end-organ damage

27 August 2021

This platform is supported by

logo Novo Nordisk